Ebola therapies and vaccines being tested by Texas Biomed

27Sep - by bi - 0 - In Health

Preclinical testing of several of the compounds used during the Ebola vaccine and therapies human clinical trials have been tested by the exas Biomedical Research Institute scientists in the Institute’s Biosafety Level 4 contract research program.

Data has shown that these compounds are efficacious to some degree. And this has become a motivational factor to carry on further testing.

In mid-August 2019, human clinical trials were halted in the current Ebola epidemic that has claimed more than 2,100 lives in Africa. The findings resulted in the discontinuation of two of the drugs in the trial. Future patients will be randomly assigned to receive either REGN-EB3 (Regeneron) or mAb114 (Ridgeback Biotherapeutics) in an extension phase of the study.

Ebola is a filovirus that causes severe hemorrhagic fever and is fatal in about half of cases. Ebola virus is one of the deadlier pathogens studied in the Biosafety Level 4 Laboratory at Texas Biomed. Scientists put in a competitive bid to use nonhuman primates to help determine the effectiveness of each of these experimental Ebola treatments. Well-documented, controlled studies involving animals are critical to licensure of Ebola therapies by the Food and Drug Administration (FDA). Texas Biomed is the only private biomedical research institute in the world with both a National Primate Research Center and a Level 4 Biosafety Lab.

The Centers for Disease Control and Prevention (CDC) classified Ebola as a Category A Bioterrorism Disease. That means the virus can be easily transmitted from person to person, results in a high mortality rate, could cause public panic and social disruption, and requires preparation for a response.